Undisclosed protein degradation therapeutic
/ Frontier Medicines, AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 05, 2023
Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie
(GlobeNewswire)
- "Frontier Medicines Corporation...announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation. These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform....Under the partnership, the companies will collaborate on the research and pre-clinical development of programs directed to novel E3 ligases, and certain immunology and oncology targets."
Licensing / partnership • Oncology
1 to 1
Of
1
Go to page
1